MedTrace Logo

Noninvasive Cardiac Radioablation for Ventricular Tachycardia Refractory to Medication and Catheter Ablation

NCT04757688 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2022-11-09

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and efficacy of cardiac radioablation (CRA) as a means of noninvasive treatment of ventricular tachycardia (VT) refractory to both medication and catheter ablation.

Conditions

  • Ventricular Tachycardia

Interventions

RADIATION

Cardiac radioablation (CRA)

CRA to 25 Gy in 1 fraction

Sponsors & Collaborators

  • Washington University School of Medicine

    collaborator OTHER

  • John Stahl

    lead OTHER

Principal Investigators

  • John Stahl, MD · University of Alabama at Birmingham (UAB)

  • Cliff Robinson, MD · Washington University School of Medicine

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-11-30
Primary Completion
2027-06-30
Completion
2028-06-30
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04757688 on ClinicalTrials.gov